Articles tagged with Heart Failure
A study by Duke University Medical Center cardiologists found that women tend to live longer with heart failure than men, having a less severe form of the disease. The research suggests that understanding these gender differences can help physicians tailor prevention or treatment strategies to specific patients.
A new study published in the New England Journal of Medicine found that patients who undergo angioplasty to open their totally blocked coronary arteries days after a heart attack do not reduce their risk of having another heart attack, going into heart failure, or dying. The study, which involved over 2,166 patients on five continents,...
A new study by Duke University Medical Center researchers found that depression itself increases mortality risk in heart failure patients, not the use of antidepressant medications. The study analyzed over 1,000 depressed patients with heart failure and found a 15% higher death rate among those who were depressed.
A study by Mayo Clinic researchers has found that people with psoriasis are more likely to develop heart disease, including heart attacks and heart failure. The study, which followed 622 adults with psoriasis and a control group of 622 people, found significant increases in cardiovascular events among those with psoriasis.
Researchers developed a seven-point system to gauge the seriousness of heart failure in elderly patients. The system estimates patient survival based on factors such as advanced age, coronary artery disease, and low blood pressure.
A study found that heart failure patients with higher systolic blood pressures had lower death rates compared to those with lower pressures. Lower systolic pressures may indicate more advanced disease and a poorer prognosis.
A study found that heart failure is associated with more common factors than previously believed, including preserved ejection fraction and diastolic dysfunction. Patients with preserved ejection fraction were older and less likely to be smokers, while those with reduced ejection fraction had higher mortality rates.
A study found that patients with low systolic blood pressure at hospital admission had poor outcomes, including higher mortality rates and rehospitalization. Higher systolic blood pressure was associated with lower risk of death in the long term.
Mayo Clinic researchers found that difficulties in the heart's ability to fill with blood are a frequent cause of heart failure, and can be just as deadly as deficiencies in pumping. The study suggests that filling problems are often undiagnosed and highlights the importance of testing for abnormalities in the heart's filling phase.
Researchers developed a treatment using mechanical Left Ventricular Assist Devices (LVADs) and certain drug therapies to shrink enlarged hearts and enable normal function. The therapy improved quality of life in 88% of patients who received the full combination, with nearly all recovering from heart disease five years later.
Patients with heart failure who started statin therapy had a 24% lower risk of death and a 21% lower risk of hospitalization compared to non-users. The study, published in JAMA, found that statins effectively lowered LDL cholesterol levels and improved clinical outcomes.
A study by Saint Louis University researchers found that heart failure drug use plummeted after two negative articles were published in prominent medical journals. The study showed that doctors quickly changed their treatment practices when confronted with potential safety risks, highlighting the significant influence of medical public...
Preliminary research suggests that famotidine, a heartburn medication, can help decrease the effects of chronic heart failure by blocking a chemical reaction that damages diseased hearts. However, more testing is required to verify the results, including dosage and safety issues.
The International Society for Heart and Lung Transplantation releases comprehensive global guidelines for managing heart failure patients prior to transplantation. The guidelines aim to enhance patient care, optimize outcomes, and improve resource allocation.
A new candidate biomarker, galectin-3, has been identified as a potential marker for heart failure diagnosis and prognosis. Elevated levels of this inflammatory protein can help diagnose heart failure and identify patients at risk of dying within 60 days.
Researchers at Thomas Jefferson University found that GRK2 protein levels are elevated in patients with failing hearts compared to those with normal heart function. The study suggests that GRK2 could be a biomarker for heart failure and potentially predict patient response to treatment.
The US FDA has approved a new totally implanted artificial heart, providing hope for patients with severe heart failure. The device is designed for those who are not eligible for a heart transplant and have a short life expectancy without the device.
A new genetic component of heart disease has been identified, with the ILK protein found to play a critical role in regulating cardiac contractility. Loss of ILK in heart cells results in cardiomyopathy and heart failure, highlighting the importance of this molecule in vital physiological processes.
A landmark study found that routine follow-up by a nurse improved heart failure patients' functionality and reduced hospitalizations. The study showed significant benefits for both African-American and Hispanic communities, with nurse-managed patients experiencing fewer limitations in physical activities.
A recent study using APPROACH data compares survival outcomes between medically treated and surgically treated patients with heart failure. The findings suggest that revascularization may not offer significant benefits in terms of risks versus benefits.
Research suggests that ACE inhibitors can reduce the risk of serious circulatory problems, including heart attack and stroke, in patients with hardening of the arteries. The benefits of ACE inhibitors for these patients are comparable to those seen in patients with existing heart failure.
Researchers have devised a new way to visualize and quantify the activity of key enzyme PKA, linked to heart failure. This innovative technique combined computer modeling with fluorescence-imaging in living cells, uncovering new details in molecular control.
A new analysis shows that digitalis is relatively safe for patients with diastolic heart failure, a condition affecting an estimated 5 million US adults. The study, involving 988 patients, found no overall detrimental effect of digitalis on death or hospitalizations.
A study by Thomas Force and his team found that Gleevec, a 'miracle' cancer drug, can cause heart failure in patients with CML due to its effect on the Abelson tyrosine kinase protein. The researchers also discovered that second-generation Gleevec drugs may have similar toxicities.
Diastolic heart failure is increasingly common, now accounting for over half of heart failure cases. Women, particularly elderly women, are disproportionately affected. Therapies for diastolic heart failure may need to be distinct from those for systolic heart failure.
Researchers at Mayo Clinic have identified a gene mutation causing chaotic electrical activation of the heart muscle and atrial fibrillation. The study found that a specific genetic mutation in the KCNA5 gene leads to susceptibility for atrial fibrillation, providing new insight into its mechanism.
Study reveals rats' hearts can withstand severe hypothermia with minimal oxygen loss, highlighting the importance of continued CPR efforts. However, prolonged exposure leads to fatal heart failure upon rewarming, suggesting improved cardiac output as a key factor in survival.
Researchers identified a common genetic variation that determines response to beta-blockers in patients with heart failure. The Arg-389 variant showed a 38% reduction in death rate among those with two copies of the gene. This discovery may lead to personalized medicine for heart failure treatment.
A study found that increased nighttime blood pressure may be associated with a higher risk of developing congestive heart failure. Analyzing data from 951 elderly men, researchers discovered that a 9–mm Hg increase in nighttime ambulatory diastolic blood pressure and non-dipping blood pressure patterns were significant predictors of CHF.
Patients who developed heart failure had almost four times the increase in risk of death during follow-up. Implantable defibrillators increased the risk of first hospitalization for heart failure and recurrent hospitalizations by 39% and 58%, respectively.
A study of nearly 600 female heart failure patients revealed that women had better outcomes with lower VO2 levels and less need for a heart transplant. The results challenge the current 'gold standard' for assessing treatment options, highlighting the importance of considering gender differences in heart failure management.
A new study found that air pollution increases the risk of death by 32% for people with diabetes, 28% for those with COPD, and 27% for those with congestive heart failure. Lowering air pollution levels can lead to improved health outcomes and longer lifespans.
Men with metabolic syndrome are nearly twice as likely to develop heart failure as those without. The condition may directly affect the heart and boost fatty deposits in arteries, say researchers. Insulin resistance is thought to play a key role in this process.
Researchers found a link between non-steroidal anti-inflammatory drugs (NSAIDs) and an increased risk of first-time hospital admissions for heart failure in the elderly. People taking indomethacin were three times more likely to be admitted due to osteoarthritis as their reason for taking NSAIDs.
A new study suggests that lixivaptan, a drug blocking vasopressin, is as effective as diuretics in reducing fluid retention in patients with congestive heart failure while also retaining proper sodium levels. The drug may offer an alternative treatment for heart failure patients and help clarify the role of vasopressin in water retention.
Researchers found that aerobic training can reverse abnormal production of certain neurohormones that cause severe symptoms of heart failure. The study suggests that exercise may be a novel non-pharmacological aid for improving functional capacity, systolic function, and quality of life in heart failure patients.
A study by University of California - San Francisco researchers found that the prostate drug doxazosin blocks alpha 1-adrenergic receptors in heart muscle cells, increasing risk of heart failure. The study suggests blocking these receptors may be a direct cause of heart failure.
Researchers analyzed data from 30,324 heart attack patients treated at U.S. hospitals and found that the BNP test was primarily used on high-risk patients with congestive heart failure or older age. However, younger and seemingly healthier patients with elevated BNP levels were at a two to four times greater risk of dying in the hospital.
Statins have been shown to significantly reduce all-cause mortality in patients treated early for acute coronary syndromes, with a moderate reduction in stroke risk. Beta-blockers also demonstrate improved survival benefits when prescribed at discharge for heart failure patients, reducing the risk of death by half.
Researchers found that early placement of cardiac resynchronization therapy devices can prolong patient lives and reduce rehospitalizations. The study analyzed data from 5,791 patients and showed a significant reduction in deaths and rehospitalizations among those who received the devices.
Recent studies have improved safety and effectiveness in treating patients with acute coronary syndromes, enhancing the management of cardiovascular disease. These advancements include innovative therapies such as bivalirudin and pexelizumab, which aim to reduce major bleeding risks while maintaining efficacy.
Researchers found that people with diabetes from different ethnic groups have varying levels of muscle mass in the left ventricle, a key indicator of heart health. In white, African-American, and Hispanic individuals, increased muscle mass was linked to subclinical atherosclerosis and high blood pressure.
A blood test measuring NT-proBNP levels can accurately predict one-year mortality risk in patients with shortness of breath, regardless of underlying heart failure diagnosis. The study suggests that this test should be routinely used to identify high-risk patients needing more intensive treatment and follow-up.
Researchers created a modified form of troponin I to improve cardiac function in mice and damaged human heart cells. The protein helps the heart respond to stress by boosting performance during periods of hardship.
A double-blind study found that acetazolamide significantly improved patient perception of sleep quality and reduced daytime fatigue in heart failure patients with sleep apnea. The medication showed promise in reducing sleep-related breathing disorders, which may also improve cardiac function.
A study found that one-third of congestive heart failure patients had low thiamin levels, highlighting the importance of diet in managing serious conditions. Vitamin supplements may help prevent thiamin deficiency and improve patient outcomes.
Researchers have developed a strategy to deliver PDGF-BB to the infarcted heart using injectable self-assembling peptide nanofibers, protecting cardiomyocytes from death and preserving cardiac function. The therapy reduced infarct size and improved cardiac function in rats.
A new blood test using NT-proBNP can accurately diagnose heart failure in patients with kidney disease, comparable to BNP testing. The study found that kidney disease does not affect the diagnostic accuracy of NT-proBNP when used properly.
The African-American Heart Failure Trial showed that patients treated with the medication had lower health care costs, averaging $15,384 over a 12-month period. The study found that the medication was cost-effective, even when factoring in the cost of the drug itself.
A CU-Boulder study found that moderate exercise extended the life expectancy of lab rats carrying a genetic blueprint for heart failure by at least 10 percent to 15 percent. This suggests low-intensity exercise may have benefits in early stages of congestive heart failure.
A study published in The Lancet found that good adherence to medication is associated with lower all-cause mortality in chronic heart failure patients. Patients who took more than 80% of their prescribed medication had a lower risk of death compared to those who took less, even when not taking any treatment.
Exercise has been shown to delay the onset of heart failure and improve survivability in rats with spontaneously hypertensive heart failure. The study also found that low-intensity exercise suppressed many physiological changes associated with CHF, including alterations in myosin heavy chain isoform expression and cardiac cell morphology.
The RAPID-CHF trial found that ultrafiltration therapy was safe and effective for patients with acute decompensated heart failure, removing more fluid and improving symptoms compared to standard treatment with intravenous diuretics. A larger trial is underway to compare its effectiveness.
A recent study by Yale University researchers found that US Medicare patients with heart failure have a lower risk of dying within 30 days compared to their Canadian counterparts. However, the difference in long-term survival rates is negligible. The study suggests that the American system may excel at acute care, while the Canadian sy...
A study published in JAMA Network found that US Medicare beneficiaries with heart failure had significantly better 30-day mortality rates compared to Canadian patients. However, one-year mortality rates were similar between the two groups.
A study of 2,730 men and women aged 70 to 79 found that subclinical hypothyroidism was associated with a higher rate of incident and recurrent congestive heart failure. In contrast, no association was found between subclinical hypothyroidism and coronary heart disease or stroke.
An international multi-center study confirmed the usefulness of a blood test in diagnosing and predicting the short-term risk of death in patients with heart failure. The study, which analyzed data from over 1,200 patients, found that the test was strongly predictive of mortality within two months of symptom onset.
Researchers found that GRK2 increases in the adrenal gland, leading to high catecholamine release and desensitization of alpha-adrenergic receptors. Reducing GRK2 levels improves receptor function and reduces catecholamine release.
A study published in the Mayo Clinic found that women with congestive heart failure are less likely to receive cardiac resynchronization therapy but survive longer after implantation. The study revealed a significant gender bias, with women outperforming men in terms of long-term survival.
A two-year study involving over 2,500 heart failure patients found that hospitals that cooperated to deliver proven care and educate patients saw lower death rates and rehospitalization rates. The project used a toolkit of standard admission orders, clinical pathways, and discharge checklists to ensure optimal care.